Empagliflozin, Dapagliflozin And Canagliflozin Market Report 2026

Empagliflozin, Dapagliflozin And Canagliflozin Market Overview

• Empagliflozin, Dapagliflozin And Canagliflozin market size has reached to $9.84 billion in 2025 • Expected to grow to $11.08 billion in 2030 at a compound annual growth rate (CAGR) of 2.4% • Growth Driver: Rising Diabetes Prevalence To Drive Growth In The Empagliflozin, Dapagliflozin, And Canagliflozin Market • Market Trend: Expanding Diabetes Care Through Innovative Pediatric Type-2 Diabetes Treatments • North America was the largest region in 2025.

What Is Covered Under Empagliflozin, Dapagliflozin And Canagliflozin Market?

Empagliflozin, dapagliflozin, and canagliflozin are medications classified as sodium-glucose co-transporter-2 (SGLT-2) inhibitors primarily used in treating type 2 diabetes mellitus. These medications are taken orally and are part of a broader diabetes management plan that includes diet, exercise, and other medications as needed. The main types of empagliflozin, dapagliflozin and canagliflozin are empagliflozin, dapagliflozin, and canagliflozin. Empagliflozin is a medication used primarily to lower blood sugar in adults with type 2 diabetes. It works by helping the kidneys remove glucose from the bloodstream through urine. The various applications include application I, application ii, application iii, and application iv and are sold through various channels such as hospitals and pharmacies.

What Is The Empagliflozin, Dapagliflozin And Canagliflozin Market Growth Forecast?

The empagliflozin, dapagliflozin and canagliflozin market size is expected to see steady growth in the next few years. It will grow to $11.08 billion in 2030 at a compound annual growth rate (CAGR) of 2.4%. The growth in the forecast period can be attributed to heart failure treatment expansion, renal protection evidence growth, diabetes combination therapy adoption, aging population, chronic disease management focus. Major trends in the forecast period include rising use of sglt-2 inhibitors in type 2 diabetes, expansion of cardiovascular benefit indications, increased preference for oral antidiabetic drugs, growth in combination diabetes therapies, strong focus on long-term glycemic control.

Global Empagliflozin, Dapagliflozin And Canagliflozin Market Segmentation

1) By Type: Empagliflozin, Dapagliflozin, Canagliflozin 2) By Application: Type 2 Diabetes Mellitus, Heart Failure, Chronic Kidney Disease, Other Applications 3) By Channel: Hospital, Pharmacy Subsegments: 1) By Empagliflozin: Standard Empagliflozin, Extended-Release Empagliflozin, Combination Empagliflozin Formulations, Generic Empagliflozin 2) By Dapagliflozin: Standard Dapagliflozin, Extended-Release Dapagliflozin, Combination Dapagliflozin Formulations, Generic Dapagliflozin 3) By Canagliflozin: Standard Canagliflozin, Extended-Release Canagliflozin, Combination Canagliflozin Formulations, Generic Canagliflozin

What Is The Driver Of The Empagliflozin, Dapagliflozin And Canagliflozin Market?

The increasing prevalence of diabetes is expected to propel the growth of the empagliflozin, dapagliflozin, and canagliflozin market going forward. Diabetes presents as a persistent health issue marked by high blood sugar levels stemming from inadequate insulin production or the body's ineffective utilization of insulin. The increasing prevalence of diabetes can be attributed to factors such as sedentary lifestyles, unhealthy dietary habits, genetic predisposition, urbanization, and aging populations, compounded by limited access to healthcare and rising obesity rates worldwide. Empagliflozin, dapagliflozin, and canagliflozin are used in diabetes management to lower blood sugar levels by inhibiting sodium-glucose co-transporter-2 (SGLT2) in the kidneys, promoting the excretion of glucose through urine. For instance, in June 2024, according to the National Health Service (NHS), UK-based government department, among individuals under 40, rising from 173,166 in 2022 to 216,440 in 2023. This significant growth highlights a concerning trend in this age group. The data reflects a rapid escalation in diabetes prevalence among younger populations. Therefore, the increasing prevalence of diabetes is driving the growth of the empagliflozin, dapagliflozin, and canagliflozin market.

Key Players In The Global Empagliflozin, Dapagliflozin And Canagliflozin Market

Major companies operating in the empagliflozin, dapagliflozin and canagliflozin market are AstraZeneca PLC, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., MSN Laboratories Private Limited, Dr Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Apotex Inc., Lupin Limited, Biocon Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Johnson & Johnson, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd., Mitsubishi Tanabe Pharma Corporation, USV Ltd., Takeda Pharmaceutical Company Limited

Global Empagliflozin, Dapagliflozin And Canagliflozin Market Trends and Insights

Major companies operating in the empagliflozin, dapagliflozin, and canagliflozin markets are focusing on developing innovative products, such as pediatric type-2 diabetes treatment, to address broader patient demographics and expand their market reach in diabetes care. Pediatric Type-2 diabetes treatment involves managing blood sugar levels through lifestyle changes, medications, and sometimes insulin therapy tailored specifically for children and adolescents. For instance, in June 2024, AstraZeneca, a UK-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) had approved Farxiga (dapagliflozin) to improve glycemic control in pediatric patients aged 10 years and older with type 2 diabetes. This approval is based on positive results from the T2NOW Phase III clinical trial, one of the most extensive pediatric type-2 diabetes trials to date, which showed that Farxiga significantly reduced HbA1c levels compared to placebo. The safety profile of Farxiga in this patient population was consistent with that observed in adults with type-2 diabetes. This approval is an important milestone, as oral treatment options for pediatric type-2 diabetes have been limited, and it underscores AstraZeneca's commitment to delivering innovative treatments across cardiovascular, renal, and metabolic diseases.

What Are Latest Mergers And Acquisitions In The Empagliflozin, Dapagliflozin And Canagliflozin Market?

In March 2024, Nirma Limited, an India-based chemical industry company that manufactures, retails, and distributes commercial and industrial cleaning products, acquired a 75% stake in Glenmark Life Sciences for an undisclosed $682 million. With this acquisition, Nirma Limited aims to enhance its presence in the pharmaceutical sector, diversify its product offerings, and leverage research and development capabilities for sustainable long-term growth. Glenmark Life Sciences is an India-based pharmaceutical company that manufactures APIs for empagliflozin, dapagliflozin, and canagliflozin, supporting diabetes treatment production.

Regional Outlook

North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Empagliflozin, Dapagliflozin And Canagliflozin Market?

The empagliflozin, dapagliflozin and canagliflozin market consists of sales of jardiance, glyxambi, synjardy, farxiga, and invokamet. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Empagliflozin, Dapagliflozin And Canagliflozin Market Report 2026?

The empagliflozin, dapagliflozin and canagliflozin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the empagliflozin, dapagliflozin and canagliflozin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.